Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,699 | -14,101 | -7,016 | -2,403 | -16,757 |
| Depreciation Amortization | N/A | N/A | N/A | N/A | 282 |
| Income taxes - deferred | -239 | N/A | N/A | -4,700 | -23 |
| Accounts payable and accrued liabilities | -2,513 | -2,112 | -2,381 | -897 | -836 |
| Other Working Capital | -8,560 | -8,099 | -10,049 | -2,946 | 5,590 |
| Other Operating Activity | 5,990 | 3,267 | 4,279 | 677 | 1,327 |
| Operating Cash Flow | $-26,021 | $-21,045 | $-15,167 | $-10,269 | $-10,417 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 12,074 | 12,024 | 9,782 | 3,000 | 38,134 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 308 |
| Financing Cash Flow | $12,074 | $12,024 | $9,782 | $3,000 | $38,442 |
| Beginning Cash Position | 35,402 | 35,402 | 35,402 | 35,402 | 7,377 |
| End Cash Position | 21,455 | 26,381 | 30,017 | 28,133 | 35,402 |
| Net Cash Flow | $-13,947 | $-9,021 | $-5,385 | $-7,269 | $28,025 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,021 | -21,045 | -15,167 | -10,269 | -10,417 |
| Free Cash Flow | -26,021 | -21,045 | -15,167 | -10,269 | -10,417 |